New drug combo aims to stop breast cancer return
NCT ID NCT03945721
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests whether adding the drug niraparib to standard radiation therapy after surgery can help prevent triple negative breast cancer from coming back. Niraparib is a PARP inhibitor that blocks cancer cells from repairing their DNA. The study includes 21 adults with residual disease after chemotherapy and surgery. The main goal is to find the safest dose of niraparib when given with radiation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Niraparib (a PARP inhibitor drug)
What this could lead to
If successful, this could lead to a new treatment option that reduces the risk of breast cancer returning after surgery and radiation.
What could go wrong
This is a very early (Phase 1) trial with only 21 participants, so safety and the right dose are the main focus. It is not yet known if the combination works better than standard care, and side effects from adding niraparib to radiation are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute/Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States